CD4 and cancer: As shown in Fig. 2c, the introduction of ABT-containing therapy facilitated a progressive decline in HIV-1 RNA from 106 copies/mL to complete suppression by May 2024, accompanied by steady improvements in CD4 + T cell counts despite concurrent chemotherapy and targeted cancer therapy.